Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Man Ao, Pengyu Li, Dongxue Sun, Xiaojun Li, Shulei Xu & Yuntao Hao. (2023) Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy. Journal of Obstetrics and Gynaecology 43:1.
Read now
Read now
Articles from other publishers (12)
Zhongqi Fan, Xinchen Zou, Guangyi Wang, Yahui Liu, Yanfang Jiang, Haoyan Wang, Ping Zhang, Feng Wei, Xiaohong Du, Meng Wang, Xiaodong Sun, Bai Ji, Xintong Hu, Liguo Chen, Peiwen Zhou, Duo Wang, Jing Bai, Xiao Xiao, Lijiao Zuo, Xuefeng Xia, Xin Yi & Guoyue Lv. (2024) A transcriptome based molecular classification scheme for cholangiocarcinoma and subtype-derived prognostic biomarker. Nature Communications 15:1.
Crossref
Crossref
Adil Parvez, Furqan Choudhary, Priyal Mudgal, Rahila Khan, Kamal A. Qureshi, Humaira Farooqi & Ashok Aspatwar. (2023) PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Frontiers in Immunology 14.
Crossref
Crossref
Zhuna Wu, Qiuya Lin, Liying Sheng, Weihong Chen, Meili Liang, Danni Wu & Yumin Ke. (2023) A novel immune-related risk-scoring system associated with the prognosis and response of cervical cancer patients treated with radiation therapy. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Ibrar Muhammad Khan, Safir Ullah Khan, Hari Siva Sai Sala, Munir Ullah Khan, Muhammad Azhar Ud Din, Samiullah Khan, Syed Shams ul Hassan, Nazir Muhammad Khan & Yong Liu. (2023) TME-targeted approaches of brain metastases and its clinical therapeutic evidence. Frontiers in Immunology 14.
Crossref
Crossref
Kun Pang, Zhen-Duo Shi, Liu-Ya Wei, Yang Dong, Yu-Yang Ma, Wei Wang, Guang-Yue Wang, Ming-Yang Cao, Jia-Jun Dong, Yu-Ang Chen, Peng Zhang, Lin Hao, Hao Xu, Deng Pan, Zhe-Sheng Chen & Cong-Hui Han. (2023) Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resistance Updates 66, pages 100907.
Crossref
Crossref
Jérémy Baude, Emeric Limagne, Riad Ladjohounlou & Céline Mirjolet. 2023.
Nam P. Nguyen, Ahmed Ali, Vincent Vinh-Hung, Olena Gorobets, Alexander Chi, Thandeka Mazibuko, Natália Migliore, Maria Vasileiou, David Lehrman, Mohammad Mohammadianpanah, Seyed Alireza Javadinia, Gokoulakrichenane Loganadane, Trinanjan Basu, Satya Bose, Ulf Karlsson & Huan Giap. (2022) Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group. Cancers 15:1, pages 244.
Crossref
Crossref
Zengfu Zhang, Xu Liu, Dawei Chen & Jinming Yu. (2022) Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Myong Hak Ri, Juan Ma & Xuejun Jin. (2021) Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer. Journal of Ethnopharmacology 281, pages 114370.
Crossref
Crossref
Yu Yuan, Abdalla Adam, Chen Zhao & Honglei Chen. (2021) Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy. Cancers 13:4, pages 663.
Crossref
Crossref
Heather R. Ferguson Bennit, Amber Gonda, Janviere Kabagwira, Laura Oppegard, David Chi, Jenniffer Licero Campbell, Marino De Leon & Nathan R. Wall. (2021) Natural Killer Cell Phenotype and Functionality Affected by Exposure to Extracellular Survivin and Lymphoma-Derived Exosomes. International Journal of Molecular Sciences 22:3, pages 1255.
Crossref
Crossref
Sridha Ganesh, Rui Wang & Honglei Chen. (2021) Dynamic Monitoring of Immunotherapy Effectiveness with Different Biomarkers in the Patients with Non-Small Cell Lung Cancer. Oncologie 23:3, pages 335-350.
Crossref
Crossref